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Abstract 
Background: We previously reported the production of transgenic rats (APP21 line) that over-express human 
amyloid precursor protein (APP) containing Swedish and Indiana mutations. In order to generate a better model for 
Alzheimer’s disease (AD), the APP21 rat line was used to generate double transgenic line that over-expressed Preseni-
lin 1 (PS1) with L166P mutation in addition to APP transgene (APP + PS1 line).
Results: Thirty-two double transgenic founders were generated and the ultimate transgenic founder was selected 
based on PS1 transgene copy number and level of amyloid-beta (Aβ)42 peptide. The APP + PS1 double transgenic 
rats had 38 times more PS1 in brains compared to APP rats. Behavioral assessment using Barnes maze showed that 
APP + PS1 rats exhibited a larger learning and memory deficit than APP21 rats. Double transgenic rats also produced 
more Aβ42. Histological examination of the brains showed that the APP21 rat line displayed neurofibrillary tangles and 
in contrast, the APP + PS1 line showed chromatolysis in hippocampal neurons and neuronal loss in CA3 region of 
hippocampus.
Conclusions: Due to the separate segregation of APP and PS1 transgenes in APP + PS1 double transgenic rats, this 
transgenic line may be a valuable model for studying the effects of various levels of APP and PS1 transgenes on vari-
ous aspects of brain pathologies associated with the AD phenotype.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Alzheimer’s disease (AD) is one of the most devastat-
ing and costly diseases that affect approximately 12 % of 
the population over the age of 65 [2]. Alzheimer’s dis-
ease is associated with the over-production and reduced 
clearance of amyloid-beta (Aβ) peptides [19]. Cleavage 
of amyloid-β precursor protein (APP) by the preseni-
lin (PS) 1 enzyme results in the release of Aβ peptides, 
which aggregate and form Aβ plaques in the brain. These 
Aβ plaques and neurofibrillary tangles are the two pri-
mary pathological manifestations of AD in the brain. 
Amyloid peptides are produced via the cleavage of APP 
by ϒ-secretase, a protease complex of four proteins that 
includes PS1 or PS2, which are both homologous pro-
teins that contain the catalytic site of the enzyme [7]. 
ϒ-secretase cleaves the β-amyloid protein into two major 
forms of Aβ polypeptides, Aβ40 and Aβ42. The relative 
amount of the longer form of Aβ, Aβ42, is particularly 
critical for AD progression because it is more prone to 
aggregation than the shorter Aβ40 peptide [4, 10, 23]. 
In addition, the ratio of Aβ42/Aβ40 correlates with the 
load of Aβ plaques in the brain [8, 14]. Furthermore, 
the reduction of PS1 mRNA using siRNA against PS1 
reduced Aβ42 in cultured cells [11] which suggests that 
lower levels of PS1 lead to decreased production of Aβ42.
We previously generated rats that overexpress human 
APP containing the Swedish and Indiana mutations [1]. 
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The APP21 line expressed high levels of APP, but failed 
to produce Aβ plaques in the brain. However, intrahip-
pocampal seeding of dilute Alzheimer brain extracts con-
taining aggregated Aβ led to the production of plaques 
in APP21 rats [20]. This finding indicates that plaque 
formation depends on environmental challenges, condi-
tions which laboratory rats are not exposed to routinely. 
In order to increase the pathogeny of overexpressed APP, 
we generated double transgenic rats from the APP21 line 
that over-express both the PS1 and the APP transgenes. 
Our hypothesis was that the addition of a PS1 transgene 
would increase more toxic Aβ42 polypeptide and thus, 
would produce a more suitable model for examining AD.
Methods
Animals, construct design, and preparation of vesicular 
stomatitis virus glycoprotein pseudotyped lentivirus
The homozygous APP21-transgenic rat line [1], con-
taining human APP with the Swedish double missense 
mutation (K595M/N596L) and Indiana single missense 
mutation (V642F), were used for the generation of APP-
PS1 double transgenic rats. Inbred Fischer 344 rats were 
used as the background strain for the APP21 rat line. The 
human PS1 cDNA coding region corresponding to 285-
1688 bases of PS1 variant 1 (GenBank Accession num-
ber NM_000021.3)  with L166P mutation was cloned 
into the Lentivial vector (pLV) containing ubiquitin-C 
(Ubi-C) and enhanced green fluorescence protein (eGFP; 
pLVU-eGFP) cassette [17] in place of the eGFP coding 
sequence. The new vector was designated as pLVU-PS1. 
The Ubi-C promoter, which is upstream of PS1, controlled 
PS1 transcription. The pLVU-PS1 was a self-inactivating 
vector, composed of the woodchuck hepatitis virus post-
transcriptional regulatory element (WRE) to increase 
transcription levels and minimize position effects. Addi-
tionally, a human immunodeficiency virus-1-flap element 
was inserted between the 5′ long terminal repeat and the 
internal promoter, which increased the titer. The prepara-
tion of vesicular stomatitis virus glycoprotein pseudotyped 
Lentivirus was as described by Lois et al. [17]. All animal 
studies were performed in accordance with the University 
of Missouri’s Animal Care and Use Committee guidelines 
and the Institute for Laboratory Animal Research Guide 
for the Care and Use of Laboratory Animals. The rats were 
housed in conventional cages at 20–25 °C in a controlled 
lighting environment and provided free access to water 
and standard pellet rodent chow.
Zygote collection, microinjection of lentiviral vector, 
and embryo transfer
Homozygous APP21-transgenic female rats (28–30 day-
old) were super ovulated by administering intraperi-
toneal (IP) injections of 15  IU pregnant mares’ serum 
gonadotropins (PMSG) followed by IP injections of 
15  IU human chorionic gonadotropin 52 h after PMSG. 
Twenty-four hours after mating, rats were euthanized 
using CO2 and zygotes were collected from the oviducts. 
Morphologically normal zygotes having two pronuclei 
and a sperm tail were used for lentiviral vector injections 
into perivitelline space as described earlier [1]. Lentiviral 
vector-injected zygotes were then transferred into the 
oviducts of 8–10 week-old Sprague–Dawley pseudopreg-
nant recipient rats.
Genomic DNA isolation and polymerase chain reaction
Genomic DNA from tail-snips was isolated using the Wiz-
ard Genomic DNA Purification Kit (Promega, Madison, 
WI). Screening of transgenic rats was conducted by PCR 
using primers annealing the Ubi-C promoter (Forward; 
TGTCCGCTAAATTCTGGCCGTT) and PS1 transgene 
(Reverse; AGCATTCAGAATTGAGTGCAGGGC). The 
PCR reactions were carried out using 50  ng genomic 
DNA, 100 ng of each primer and 1.5 U Biolase taq (Bio-
line, Randolph, MA), and amplified PCR products were 
size separated through a 1 % agarose gel stained with eth-
idium bromide for visualization.
ELISA measurement of Aβ40 and Aβ42
Serum samples were analyzed for Aβ40 and Aβ42 using 
commercial ELISA kits (Genetics Company, Schlieren, 
Switzerland). Serum samples were diluted in assay buffer 
and processed according to the manufacturer’s recom-
mended protocols. Briefly, samples and standards were 
incubated in capture wells overnight at 4  °C with either 
a biotinylated Aβ40 or an Aβ42-specific antibody. After 
several rinses, the enzyme-conjugated detection rea-
gent was added to the wells for 30 min. After additional 
rinses, wells were incubated with the chromogen solution 
for 30 min at room temperature and were shielded from 
light. After the addition of the stop solution, the wells 
were read for absorption at 450 nm and the Aβ concen-
tration in the samples was calculated based on standard 
curves.
Southern blot analysis
Southern blot analysis was conducted to determine the 
copy number of the transgene in founder rats. Genomic 
DNA was digested with EcoRI, which cut the junction of 
the PS1 and the WRE transgene. The digestion products 
were size-separated through a 0.8 % agarose gel and trans-
ferred to a Genescreen plus membrane (Perkin Elmer, 
Wellesley, MA) overnight. The 524  bp PS1 probe tem-
plate was prepared by amplification of pLVU-PS1 using 
forward (AGGTCCACTTCGTATGCTGGTTGA) and 
reverse (TGATGGAGATTGGAAGAGTGGCA) prim-
ers. The 32P labeled probe was generated using the probe 
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template, Ready-To-Go DNA Labeling Beads (Amersham 
Biosciences, Piscataway, NJ) and [α-32P]-dCTP (Perkin 
Elmer, Wellesley, MA). The membranes were prehybrid-
ized in 10  % dextran sulfate, 6  ×  saline sodium sitrate 
(SSC), 1  % sodium dodecyl sulfate (SDS) for 2  h and 
hybridized using the 32P labeled probe overnight before 
exposure to BioMax MS-1 Autoradiography Film (Kodak, 
Rochester, NY).
Northern blot analysis
Total RNA was isolated using Trisure (Bioline, CA) from 
founder APP21 + PS1 and APP21 transgenic rats. Brain, 
heart, kidney, liver, and lung tissues were used in North-
ern blot analysis. Total RNA was size-separated through 
1  % agarose gel before transferring to the Genescreen 
plus membrane overnight. The membrane was prehy-
bridized in 10 % dextran sulfate, 5 × SSPE, 50 % forma-
mide, 5 × Denhardt’s, 1 % SDS at 42 °C for 6 h prior to 
hybridization with the PS1 probe overnight. After expo-
sure to BioMax MS-1 Autoradiography Film, membranes 
were stripped to remove labeled cDNA probe by boil-
ing for 1 h in 1 %SDS and 0.1× SSC. The intensity of the 
bands was determined using Kodak 1D v 3.6.3 software 
(New Haven, CT).
Behavioral measures
Behavioral assessment was conducted using APP + PS1 
(n = 12), APP (n = 11), and non-transgenic Fischer 344 
(n = 12) rats when their average age was approximately 
10 months. Prior to behavior studies, each rat was han-
dled at least 3 times to reduce stress due to handling dur-
ing the behavioral testing.
Barnes maze
The maze consisted of a grey circular platform 122 cm in 
diameter. The platform was surrounded by a wall that was 
30.5 cm in height. The maze was elevated 83.8 cm above 
the floor by a stand. Twenty holes measuring 10.2 cm in 
diameter were evenly spaced around the perimeter. A 
rectangular grey escape box (28 cm in length × 12.7 cm 
wide × 7.6 cm high at the area closest to the maze taper-
ing to 16.5  cm high) could be placed beneath any hole. 
The escape box included an entry ramp that provided 
easy entry access for the rat. Black curtains were hung 
around the maze and above the maze walls to surround 
the apparatus and ensure that rats could only use the 
visual cues provided in the maze, rather than the distal 
cues within the testing room. Proximal cues were more 
likely to remain constant, within subjects and across sub-
jects, during the course of training. Four visual cues con-
sisting of various shapes (triangle, square, circle, cross) 
were placed at evenly spaced intervals on the inside of the 
maze walls. Two 86-W, 120-V floodlights producing 1690 
lumins were hung above the platform served to brightly 
light the maze in order to create a potentially aversive 
environment to help motivate the rats to escape from the 
brightly lit, open surface in favor of the dark environment 
of the escape box. One light hung 68.5 on side of the 
maze while the other hung 137 cm from the other side.
Each rat was assigned an escape hole number under 
which the escape box was placed on each test trial; 
assigned hole numbers were alternated across rats to 
eliminate odor cues for consecutively tested rats. The 
escape box location remained constant for any individual 
rat across test trials. Behavioral testing consisted of two 
pretraining trials on the first day, and 6 evaluation trials 
(2 trials/day) over a period of 3 days. Each day, the ani-
mals were transferred in their home cage from their col-
ony room to the testing room 30 min prior to the start of 
testing. On the pretraining trial, the rat was preexposed 
to the goal box (with the goal box placed in the same 
hole that would be used during subsequent training) by 
placing the rat in the goal box for 90 s. The rats’ escape 
from the goal box was prevented by covering the open-
ing to the maze surface with a grey, opaque start box (a 
23  cm ×  23  cm box). A training trial began by placing 
the rat under the start box positioned in the center of the 
platform. After 30 s, the box was lifted and the rat had a 
maximum of 5 min (300 s) to locate and enter the escape 
box. Latency (time it took for the rat to find and enter the 
escape box) and total errors (nose-pokes into non-escape 
holes) were recorded. If the rat did not enter the escape 
box within 5 min, it was gently guided there by the exper-
imenter’s hand. After 30  s, the rat was removed from 
the escape box and returned to its home cage. Rats were 
allowed to rest in their home cage in the testing room for 
30 min before starting their second daily trial. The plat-
form and escape box were cleaned after every trial with a 
20 % ethanol solution. After the third day, testing abated 
for 3  days, after which retention was evaluated for two 
additional trials (1 day), conducted exactly like those just 
described. The following day, the rats were given reversal 
training in which the rats were given training exactly like 
those of original acquisition, except that the escape box 
was located in a new location (in the opposite quadrant). 
Reversal training continued for a total of 3 days.
Histopathology
Nine of the female rats [3 of each: APP + PS1, APP, and 
wild type (WT)] were euthanized at 18–19 months of age 
and their brains were collected. Tissues were fixed in 10 % 
formalin for 48 h prior to paraffin embedding. Hematox-
ylin and eosin staining was used to determine histological 
changes. The stained slides were analyzed using a Nikon 
Eclipse E600 microscope (Melville, NY) and an Olympus 
DP72 Camera (Center Valley, PA).
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Statistical analysis
Statistical analysis for PS1 mRNA expression, serum Aβ 
level comparisons, and behavioral analyses were per-
formed using general linear models in SAS (SAS 9.3, SAS 
Institute Inc., Cary, NC, USA). For the Barnes maze, the 
average of each animal’s daily score was used in the anal-
ysis of overall performance during acquisition and rever-
sal training. Comparisons of daily performance were 
analyzed separately and differences were considered sig-
nificant at p < 0.05 for all analyses.
Results
APP21‑PS1 double transgenic founders
Forty-five rats were born from the lentiviral vector which 
contained PS1 transgene-injected embryos and 32 of 
them were PCR positive for the PS1 transgene. Southern 
blot results showed that transgene copy number ranged 
between 1 and 5 for each PS1 transgenic founder rat 
(Fig. 1a). Serum Aβ42 ranged between 25 and 479 pg/ml 
in the founder animals at 4  weeks of age and transgene 
copy number positively correlated with serum AB42 lev-
els in founder animals (r  =  .54). Serum Aβ40 and Aβ42 
levels at 8 weeks of age were also determined in founder 
animals (Fig. 1b). Due to the segregation of multiple inte-
gration sites in subsequent generations of transgenic 
animals, founder animals with one copy transgene were 
used for breeding. Founders with one PS1 transgene copy 
and relatively high serum Aβ42 levels were considered in 
order to determine the ultimate founder animal. Founder 
964 had one of the highest serum Aβ42 (196 pg/ml) lev-
els as well as Aβ42/Aβ40 levels (0.28) at 8  weeks of age. 
Furthermore, the F1 generation from founder 964 had 
the highest serum Aβ42 levels and had a relatively large-
sized litter. Thus, founder 964 was used as the transgenic 
founder for generation of APP + PS1 transgenic rats.
Northern blot analysis of various tissues from the 
founder APP  +  PS1 transgenic animals showed that 
brain, heart, kidney, liver, and lung had 38, 8, 19, 15, and 
15 fold more PS1 mRNA (P  <  0.01), respectively, com-
pared to the APP21 rat line. Serum Aβ40 and Aβ42 lev-
els at 8 weeks were positively correlated with PS1 mRNA 
levels in APP + PS1 founders (Table 1). Statistical anal-
ysis of the PS1 expression of founder animals was done 
by grouping the animals based on their 8 wk serum Aβ42 
levels. The groups comprised of rats with Aβ42 serum 
levels of less than 100  pg/ml (<100), between 100 and 
149 pg/ml (100–149), between 150 and 200 pg/ml (150–
200), and greater than 200 pg/ml (>200), as well as APP21 
rats that did not have the PS1 transgene. PS1 expression 
in tissues increased significantly (p < 0.05) as serum Aβ42 
levels increased (Fig. 2; Additional file 1: Table 1) with the 
exception of the liver, in which PS1 levels were not sig-
nificantly different.
Subsequent generations of APP + PS1 double transgenic 
rat line
The APP21 line has been previously bred as a homozy-
gous transgenic line. However, homozygous APP + PS1 
rats failed to produce pups. Thus, the APP +  PS1 dou-
ble transgenic line was retained as homozygous for APP 
transgene and hemizygous for PS1 transgene.
Serum Aβ40 and Aβ42 levels were determined in 
F1 generation pups at 30  days of age and in F2 gen-
eration pups at 50  days of age (Fig.  3; Additional file  2: 
Table 2). The Aβ42 levels increased with age in both APP 
and APP  +  PS1 lines and both F1 and F2 generation 
APP + PS1 rats had significantly greater (p < 0.05) Aβ42 
levels compared to APP rats. Serum Aβ42/Aβ40 levels 
were approximately two times greater in the APP + PS1 
rats compared to the APP rats for both F1 and F2 gen-
erations (p  <  0.001), but serum Aβ40 levels were similar 
between PS1  +  APP and APP rats and did not change 
with age.
Behavior changes among AP + PS1, PS and fischer wild 
type rats
Barnes maze
There were no statistical differences in performance 
between male and female rats, thus the data were col-
lapsed over sex for all of the behavioral analyses.
Acquisition Overall, APP  +  PS1 rats made signifi-
cantly more errors compared to WT rats (p = 0.04) dur-
ing acquisition training, but there were no group differ-
ences in latency (p > 0.05; Fig. 4a). More specifically, there 
were no statistical differences in performance among the 
groups on acquisition days 1 and 2 (ps > 0.05), however, 
on day 3, APP + PS1 rats made significantly more errors 
compared to both APP and WT rats (p < 0.001) and had 
significantly longer latencies compared to WT rats only 
(p = 0.02; Fig. 4d). Overall, these results suggest that the 
APP + PS1 rats had a larger learning deficit in the Barnes 
maze task than the APP rats.
Retention After the retention interval, APP + PS1 rats 
made numerically more errors (p = 0.1) and had signifi-
cantly longer latencies (p = 0.01) than both the APP and 
WT rats (Fig. 4b), implying a larger memory deficit in the 
APP + PS1 rats. These differences in memory retention 
may be due to the larger learning deficit in APP + PS1 ani-
mals during acquisition training.
Reversal Overall, APP  +  PS1 rats made significantly 
more errors (p = 0.04) and had significantly longer laten-
cies (p = 0.03) compared to both the WT and APP rats 
during reversal training (Fig. 4c). More specifically, there 
were no significant differences on days 1 and 2 of reversal 
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training (ps > 0.05), but on day 3, APP + PS1 rats made 
significantly more errors (p < 0.01) and had significantly 
longer latencies (p =  0.04) than both the APP and WT 
rats (Fig.  4e). These results suggest deficits in reversal 
learning in the APP + PS1 rats. Additional file 3: Table 3 
contains the dataset of the Barnes Maze.
Histopathology of brain
The hippocampal pyramidal cell layer of Cornu Ammonis 
(CA) 1 and CA2 regions of the APP transgenic rats con-
tained many necrotic neurons and neurofibrillary tan-
gles (Fig.  5a, d, and g). Mineralization was also evident 
as indicated by the rough cell membrane observed in 
some of the neurons in the hippocampus and the cortex 
in both the APP and the APP + PS1 rats. In addition to 
neurons containing flame-shaped neurofibrillary tangles, 
hippocampus also contained remnants of neurofibrillary 
tangles that were embedded in the neuropil (ghost tan-
gles) in the APP rats (Fig. 5d, g). Neurofibrillary tangles 
were present in viable cells that had nuclei as well as neu-
rons with no visible nuclei (Fig. 5). The CA3 region also 
contained necrotic neurons and neurofibrillary tangles in 
both the APP and APP + PS1 rats (Fig. 5j, k).
Both the APP and APP + PS1 rats had fewer pyrami-
dal neurons in the CA3 region compared to WT, but 
Fig. 1 a Southern blot analysis of the genomic DNA of the founder animals used to determine the copy number of PS1 transgene. The copy num-
ber of the PS1 transgene was determined by the number of hybridized genomic DNA segments in the autoradiogram and is shown in parenthesis 
above the rat numbers. M represents the molecular weight (MW) markers. b Serum Aβ42/Aβ40 levels of APP + PS1 double transgenic founder 
animals and APP21 rats at 8 weeks of age. The Aβ42/Aβ40 ratio for rat 988 could not be determined because its Aβ42 level was lower than the detec-
tion limit of the test. Founder 964 was selected based on having one PS1 transgene and high Aβ42/Aβ40 levels as well as for having a large litter with 
high Aβ42/Aβ40 levels
Table 1 Correlation coefficients of  serum Aβ42 and  Aβ40 
levels to PS1 mRNA levels of the organs
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the APP +  PS1 animals had more severe neuronal loss 
in the CA3 region (Fig. 5b). The hippocampal pyramidal 
cell layer in the APP + PS1 rats had many neurons with 
central and segmental chromatolysis, showing eccentric 
displacement of the nucleus and loss of Nissl substance 
with the exception of the margins of the cell body (Fig. 5h, 
k). Both the APP and the APP + PS1 brain cortex con-
tained neurons with various degrees of degeneration that 
ranged from neurons with condensed Nissl substance to 
dark necrotic neurons and ghost tangles (Fig. 5p, q). The 
brain cortex of the APP + PS1 animals had larger areas 
with dark stained neurons, which indicated more severe 
neuronal necrosis (Fig. 5q).
Discussion
The production of transgenic rats using lentiviral vec-
tors is an efficient method for gene transfer. However, the 
major drawback of lentiviral vectors is the integration of 
the transgene into multiple sites of the genome. Multiple 
copies of the transgene result in high levels of expression, 
but segregation in subsequent generations drastically 
decreases transgene expression. In this study, the founder 
animal was selected among the animals that had only one 
copy of the transgene and those that also had the greatest 
serum Aβ42 levels and Aβ42/Aβ40 ratio.
Serum Aβ42 and Aβ40 levels were positively correlated 
with PS1 mRNA expression, indicating that the addition 
Fig. 2 PS1 expression in founder animals and APP controls as deter-
mined by Northern blot analysis. The expression of PS1 was analyzed 
by combining animals with similar serum Aβ42 levels and statistical 
analysis conducted for each tissue. The figure legend indicates the 
range of serum Aβ42 level (pg/ml) of the founder animals or the APP 
control rats. Different letters above each bar indicates significantly dif-
ferent (p < 0.05) expression
Fig. 3 Serum Aβ42 (A, D), Aβ40 (B, E) and Aβ42/Aβ40 (C, F) levels of 30 day old F1 and 50 day old F2 generations. Different letters above each bar 
indicate significantly different levels of Aβ42 and Aβ42/Aβ40
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of the PS1 transgene contributed to the production of 
both Aβ42 and Aβ40. Furthermore, the greater correlation 
efficiencies for Aβ42 and PS1 mRNA expression indicate 
preferential cleavage of Aβ42 by the PS1 enzyme. Trans-
fection using PS1 resulted in an approximately 1.6 fold 
increase in Aβ42/Aβ40 levels [16] in cell cultures. Simi-
larly, the APP  +  PS1 transgenic animals had approxi-
mately a twofold Aβ42/Aβ40 increase compared to the 
APP rats. The level of PS1 mRNA expression varied by 
tissue with the highest PS1 expression in the brain and 
kidney, while the heart and liver had lower expression. 
Tissue specific expression was also observed in the APP 
transgenic rats [1].
Histologic examination of the brains showed that 
both the APP and the APP  +  PS1 animals exhibited 
pathological abnormalities typically associated with AD. 
Interestingly, the APP rats had large hippocampal sec-
tions containing neurons with neurofibrillary tangles. 
The hippocampus of the APP + PS1 rats also contained 
neurofibrillary tangles, but these were more sporadic 
compared to what was observed in the APP rats. Interest-
ingly, neuronal loss was much greater in the CA3 region 
of the APP +  PS1 rats. Another difference between the 
hippocampus in APP and the APP  +  PS1 animals was 
that neurons in the CA1 and the CA2 regions of the 
APP + PS1 animals had chromatolysis. Chromatolysis is 
Fig. 4 Overall performance of Barnes maze Acquisition Training (A) Retention (B), and Reversal Training (C). Daily performance of Acquisition Train-
ing (D), and Reversal Training (E). Data is expressed as group mean ± SEM. Different letters above each bar indicates significantly different (p < 0.05) 
expression
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caused by axonal injury in motor neurons [18] and it has 
been associated with neurotoxicity and AD [5, 15, 22], 
but it is not reported as widely as the presence of neurofi-
brillary tangles or Aβ plaques.
A previously reported rat model for AD, the TgF344-
AD model [6], was found to produce plaques at 
15 months. The difference in plaque production between 
the TgF344-AD and the APP + PS1 rats could be due to 
the fact that the PS1 transgene in the TgF344-AD had Δ 
exon 9 mutation, as opposed to the L166P mutation form 
of the PS1 transgene that was used in these APP + PS1 
rats. On the other hand, the behavioral characteriza-
tion of the APP + PS1 rats in this current study revealed 
learning and memory deficits similar to what has been 
found in TgF344-AD rats. In addition, previous research 
has found that an AD mouse model that did not develop 
plaques even as late as 30 months old also showed mem-
ory deficits [9]. Consequently, the presence of Aβ plaques 
may not always correlate with AD severity. For exam-
ple, Shankar et  al. [21] showed that Aβ dimers are syn-
aptotoxic and disrupted memory, whereas insoluble Aβ 
plaque cores from Alzheimer’s diseased cortex did not 
impair long-term potentiation. Furthermore, the number 
of Aβ plaques in the brain has not been found to corre-
late with the severity of cognitive impairments in humans 
or in APP and/or PS transgenic mice [3].
Wild type rats outperformed both the APP and the 
APP +  PS1 rats during the initial learning phase of the 
Barnes maze test. Additionally, retention of the learned 
task was poorer in the APP + PS1 rats relative to both the 
APP and the WT rats. As stated earlier, one of the major 
differences between the APP + PS1 and the APP rats was 
that the APP +  PS1 rats had neuronal loss in the CA3 
region of hippocampus (Fig.  5b shows an APP  +  PS1 
rat with very few neurons in the CA3 region). The CA1 
region recodes information from the CA3 region and sets 
up associatively learned backprojections to the neocortex 
to allow subsequent retrieval of information to the neo-
cortex [13]. The hippocampal CA3 region and the den-
tate gyrus also play an important role in the encoding 
of new spatial information and processing the geometry 
of the environment [12], which are both crucial to the 
successful completion of the task. Thus, the differences 
between the APP + PS1, APP, and WT rats in learning 
and retention in the task may be related to the differences 
in the pathology of the hippocampus.
Conclusions
The addition of the PS1 transgene to the APP transgenic 
rat genome affected serum Aβ42 and Aβ42/Aβ40 levels, 
brain histopathology, as well as, the cognitive behavior 
of the double transgenic rats. Although the APP rat brain 
had many histopathogical abnormalities that are often 
seen in AD brains, their memory did not show significant 
impairment during the behavioral testing. In contrast, 
the APP + PS1 rats showed significantly reduced mem-
ory retention compared to the APP and the WT rats, in 
addition to, neuronal loss and necrosis in the hippocam-
pus and brain cortex.
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